Mepred 1g Injection contains Methylprednisolone 1000mg, a potent synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. It is indicated for the management of various inflammatory, allergic, and autoimmune conditions, including severe asthma exacerbations, acute allergic reactions, rheumatoid arthritis, systemic lupus erythematosus, and certain dermatologic disorders. Methylprednisolone exerts its effects by modulating the expression of anti-inflammatory proteins and suppressing pro-inflammatory mediators, thereby reducing tissue inflammation and immune response. Mepred 1g Injection is administered intravenously, allowing rapid onset of action, making it suitable for acute and severe presentations requiring prompt intervention. Dosage and duration of therapy should be individualized based on the patient’s clinical condition and response, with careful monitoring to minimize potential adverse effects such as immunosuppression, hyperglycemia, hypertension, and electrolyte imbalances. Caution is advised in patients with infections, diabetes, osteoporosis, or peptic ulcer disease. Abrupt discontinuation should be avoided to prevent adrenal insufficiency; tapering is recommended following prolonged use. Mepred 1g Injection should be used under strict medical supervision, ensuring appropriate patient evaluation and monitoring throughout treatment to optimize therapeutic outcomes and minimize risks.